Novel Gelatin-based Nano-gels with Coordination-induced Drug Loading for Intracellular Delivery

doi:10.1016/j.jmst.2016.04.009

Abstract

Abstract:

In this study, we develop the gelatin-dopamine (Gel-Dopa) nano-gels (GDNGs) and explore their potential as drug delivery vehicles. The Gel-Dopa precursor is synthesized using EDC/NHS coupling reaction, in which the catechols can coordinate with transition metal ions such as Fe³⁺. These novel GDNGs exhibit excellent cytocompatibility. The model drug, doxorubicin (Dox), is readily conjugated into catechol of GDNGs by the coordination cross-link of Fe³⁺ ion. The morphology and size distribution of the nano-gels are characterized via field emission scanning electron microscopy and particle size analyzer, respectively. The GDNGs loaded with Dox (GDNGs-Dox) is capable of efficiently penetrating cell membrane and enter the HeLa cells. The endocytosed GDNGs-Dox release Dox molecules and subsequently kill the tumor cells.

Key words: Gelatin, Dopamine, Doxorubicin, Coordination interaction, Drug delivery

Fan Changjiang,Wang Dong-An. Novel Gelatin-based Nano-gels with Coordination-induced Drug Loading for Intracellular Delivery[J]. J. Mater. Sci. Technol., 2016, 32(9): 840-844.

Figures/Tables 6

Fig. 1. (A) Synthesis scheme of Gel-Dopa precursor via EDC/NHS chemistry. (B) Schematic fabrication process of GDNGs-Dox from Gel-Dopa precursor: (a) GDNGs are first synthesized via a desolvation method; subsequently, (b) the GDNGs suspension is stirred with Dox in the presence of FeCl3, achieving GDNGs-Dox. (C) Schematic illustration of targeting and endocytic process of GDNGs-Dox by a tumor cell.

Fig. 2. (A) Schematic structure of the Gel-Dopa precursor: 1H NMR spectra of Gel-Dopa (B) and gelatin (C), respectively.

Fig. 3. (A) FESEM image of the GDNGs: size distribution of GDNGs (B) and GDNGs-Dox (C).

Fig. 4. Viability of HeLa cells incubated with GDNGs suspension in a concentration range from 10 to 50?μg/mL.

Fig. 5. Fluorescent micrographs of the HeLa cells incubated with GDNGs-Dox suspension, in which the relative Dox concentration is increased from 1.0 (a) to 2.0 (b), 5.0 (c), 10 (d), 20 (e), and 30 (f) μg/mL. Scale bar is 200?μm.

Fig. 6. Viability of the HeLa cells after treatments with free Dox or GDNGs-Dox for 24 (A) and 48?h (B), respectively.

References

[1]	E.A. Murphy, B.K. Majeti, L.A. Barnes, M. Makale, S.M. Weis, K. Lutu-Fuga, W. Wrasidlo, D.A. Cheresh.Proc. Natl. Acad. Sci. U.S.A., 105(2008), pp. 9343-9348
[2]	S. Lefevre, A. Knedla, C. Tennie, A. Kampmann, C. Wunrau, R. Dinser, A. Korb, E.M. Schnaeker, I.H. Tarner, P.D. Robbins, C.H. Evans, H. Stuerz, J. Steinmeyer, S. Gay, J. Schoelmerich, T. Pap, U. Mueller-Ladner, E. Neumann. Nat.Med, 15(2009) 1414-U1410
[3]	K.S. Soppimath, T.M. Aminabhavi, A.R. Kulkarni, W.E. Rudzinski. J. Control.Release, 70(2001), pp. 1-20
[4]	D. Olsen, C.L. Yang, M. Bodo, R. Chang, S. Leigh, J. Baez, D. Carmichael, M. Perala, E.R. Hamalainen, M. Jarvinen, J. Polarek. Adv.Drug Delivery Rev, 55(2003), pp. 1547-1567
[5]	M. Jahanshahi, Z. Babaei. Afr.J. Biotechnol, 7(2008), pp. 4926-4934
[6]	A.O. Elzoghby, W.M. Samy, N.A. Elgindy. J. Control.Release, 161(2012), pp. 38-49
[7]	R.W. Moskowitz.Semin. Arthritis Rheu, 30(2000), pp. 87-99
[8]	A.O. Elzoghby. J. Control.Release, 172(2013), pp. 1075-1091
[9]	E. Leo, M.A. Vandelli, R. Cameroni, F. Forni. Int.J. Pharm, 155(1997), pp. 75-82
[10]	H. Zhou, X. Sun, L. Zhang, P. Zhang, J. Li, Y.N. Liu.Langmuir, 28(2012), pp. 14553-14561
[11]	N.T. Qazvini, S. Zinatloo. J.Mater. Sci. Mater. Med, 22(2011), pp. 63-69
[12]	C. Coester, P. Nayyar, J. Samuel. Eur. J. Pharm.Biopharm, 62(2006), pp. 306-314
[13]	G. Kaul, M. Amiji. Pharm.Res, 19(2002), pp. 1061-1067
[14]	Z. Lu, T.K. Yeh, M. Tsai, J.L.S.Au, M.G. Wientjes. Clin. Cancer Res, 10(2004), pp. 7677-7684
[15]	Y.C. Chen, S.H. Yu, G.J. Tsai, D.W. Tang, F.L. Mi, Y.P. Peng. J. Agric.Food Chem, 58(2010), pp. 6728-6734
[16]	Z. Li, L. Gu. J.Agric. Food Chem, 59(2011), pp. 4225-4231
[17]	J. Choubey, A.K. Bajpai. J. Mater. Sci.Mater. Med, 21(2010), pp. 1573-1586
[18]	F. Novio, J. Simmchen, N. Vazquez-Mera, L. Amorin-Ferre, D. Ruiz-Molina.Coord. Chem. Rev, 257(2013), pp. 2839-2847
[19]	Z. Ma, B. Moulton. Coord.Chem. Rev, 255(2011), pp. 1623-1641
[20]	W.J. Rieter, K.M. Pott, K.M.L.Taylor, W. Lin. J. Am. Chem. Soc, 130(2008), pp. 11584-11585
[21]	H. Qiao, M. Sun, Z. Su, Y. Xie, M. Chen, L. Zong, Y. Gao, H. Li, J. Qi, Q. Zhao, X. Gu, Q. Ping.Biomaterials, 35(2014), pp. 7157-7171
[22]	L. Xing, H. Zheng, S. Che. Chem.Eur. J., 17(2011), pp. 7271-7275
[23]	X.H. Wang, D.P. Li, W.J. Wang, Q.L. Feng, F.Z. Cui, Y.X. Xu, X.H. Song, M. van der Werf. Biomaterials, 24(2003), pp. 3213-3220
[24]	S. Hong, K. Yang, B. Kang, C. Lee, I.T. Song, E. Byun, K.I. Park, S.W. Cho, H. Lee. Adv.Funct. Mater, 23(2013), pp. 1774-1780
[25]	S. Balthasar, K. Michaelis, N. Dinauer, H. von Briesen, J. Kreuter, K. Langer. Biomaterials, 26(2005), pp. 2723-2732
[26]	L.S. del Rosario, B. Demirdirek, A. Harmon, D. Orban, K.E. Uhrich. Macromol. Biosci, 10(2010), pp. 415-423
[27]	H. Murakami, M. Kobayashi, H. Takeuchi, Y. Kawashima. Int.J. Pharm, 187(1999), pp. 143-152
[28]	L.H. Liu, Z.Y. Li, L. Rong, S.Y. Qin, Q. Lei, H. Cheng, X. Zhou, R.X. Zhuo, X.Z. Zhang.ACS Macro Lett, 3(2014), pp. 467-471
[29]	Y.J. Cheng, G.F. Luo, J.Y. Zhu, X.D. Xu, X. Zeng, D.B. Cheng, Y.M. Li, Y. Wu, X.Z. Zhang, R.X. Zhuo, F. He.ACS Appl. Mater. Interfaces, 7(2015), pp. 9078-9087
[30]	J. Liang, W.L. Wu, X.D. Xu, R.X. Zhuo, X.Z. Zhang.Colloids Surf. B Biointerfaces, 114(2014), pp. 398-403
[31]	D.S. Kohane, R. Langer. Chem.Sci, 1(2010), pp. 441-446
[32]	B.B. Hasinoff.Biochem. Cell Biol, 68(1990), pp. 1331-1336
[33]	G.C. Pereira, A.M. Silva, C.V. Diogo, F.S. Carvalho, P. Monteiro, P.J. Oliveira.Curr. Pharm. Des, 17(2011), pp. 2113-2129
[34]	H.Z. Jia, J.Y. Zhu, X.L. Wang, H. Cheng, G. Chen, Y.F. Zhao, X. Zeng, J. Feng, X.Z. Zhang, R.X. Zhuo.Biomaterials, 35(2014), pp. 5240-5249